







an Open Access Journal by MDPI

# Arbovirus Vaccines That Circulate within the Same Ecological Niche: Zika, Dengue & Chikungunya

Guest Editors:

## Prof. Dr. Martin F. Bachmann

RIA, Immunology, University Hospital, Bern, Switzerland

## Dr. Byron Martina

Department of Viroscience, Postgraduate School Molecular Medicine, Erasmus University Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands

Deadline for manuscript submissions:

closed (29 February 2020)

# **Message from the Guest Editors**

Dear Colleagues,

Arthropod-borne viruses, also named arboviruses, are distributed worldwide and represent a global health burden. Arboviruses have a broad distribution within warmer regions of the world, and many of these viruses are found in the same environment and are transmitted to vertebrate hosts by the same vector, for example, the Zika, Dengue, and Chikungunya viruses are all transmitted to humans by Aedes mosquitoes.

In addition to transmission by the same vector, arboviruses share a considerable genetic similarity, as well as clinical manifestations, making their diagnostic and treatment more complex. Hence, prophylactic tools, such as vaccine development, and vector control appear to be the best way to control their presence and prevent their spread to a new environment.

Prof. Martin F Bachmann Dr. Byron Martina *Guest Editors* 







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

### **Contact Us**